Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway

(2015) Emma M. Smith et al.   Oncotarget

The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling

(2015) Neil Rajan et al.   Oncotarget

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Improved vectors and genome-wide libraries for CRISPR screening

(2014) Neville E Sanjana et al.   NATURE METHODS

JEPETTO: a Cytoscape plugin for gene set enrichment and topological analysis based on interaction networks

(2013) Charles Winterhalter et al.   BIOINFORMATICS

Decoding the Pathophysiology and the Genetics of Multiple Myeloma to Identify New Therapeutic Targets

(2013) Panisinee Lawasut et al.   SEMINARS IN ONCOLOGY

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

(2012) S. Kumar et al.   BLOOD

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Transcriptional Silencing of the Wnt-Antagonist DKK1 by Promoter Methylation Is Associated with Enhanced Wnt Signaling in Advanced Multiple Myeloma

(2012) Kinga A. Kocemba et al.   PLoS One

Targeted Disruption of the BCL9/ -Catenin Complex Inhibits Oncogenic Wnt Signaling

(2012) K. Takada et al.   Science Translational Medicine

CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt

(2012) Jae Hyang Lim et al.   Nature Communications

CYLD: a deubiquitination enzyme with multiple roles in cancer

(2011) Ramin Massoumi   Future Oncology

Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling

(2011) Wim de Lau et al.   NATURE

R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/ -catenin signaling

(2011) K. S. Carmon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Notch/Hes1 Pathway Sustains NF-κB Activation through CYLD Repression in T Cell Leukemia

(2010) Lluis Espinosa et al.   CANCER CELL

STAT3 Activation of miR-21 and miR-181b-1 via PTEN and CYLD Are Part of the Epigenetic Switch Linking Inflammation to Cancer

(2010) Dimitrios Iliopoulos et al.   MOLECULAR CELL

Loss of the Tumor Suppressor CYLD Enhances Wnt/β-Catenin Signaling through K63-Linked Ubiquitination of Dvl

(2010) Daniele V.F. Tauriello et al.   MOLECULAR CELL

Frameshift mutations of ATBF1, WNT9A, CYLD and PARK2 in gastric and colorectal carcinomas with high microsatellite instability

(2010) Chang Hyeok An et al.   PATHOLOGY

Aurora kinase A is a target of Wnt/ -catenin involved in multiple myeloma disease progression

(2009) J. Dutta-Simmons et al.   BLOOD

Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma

(2009) E. Jost et al.   CANCER LETTERS

Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma

(2009) Ramin Massoumi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Phosphorylation of the Tumor Suppressor CYLD by the Breast Cancer Oncogene IKKɛ Promotes Cell Transformation

(2009) Jessica E. Hutti et al.   MOLECULAR CELL